Paul Choi
Stock Analyst at Goldman Sachs
(3.49)
# 912
Out of 5,139 analysts
109
Total ratings
52.17%
Success rate
5.41%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintains: Buy | $55 → $95 | $46.51 | +104.26% | 1 | Dec 19, 2025 | |
| CYTK Cytokinetics | Upgrades: Buy | $55 → $95 | $62.58 | +51.81% | 3 | Dec 19, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $44 → $50 | $72.48 | -31.02% | 8 | Nov 5, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $55 → $100 | $76.26 | +31.13% | 7 | Oct 31, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $55 | $39.41 | +39.56% | 2 | Oct 29, 2025 | |
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $12.20 | -50.82% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $64.25 | +19.84% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $27.39 | -26.98% | 1 | Sep 25, 2025 | |
| EXEL Exelixis | Initiates: Buy | $47 | $43.96 | +6.92% | 1 | Sep 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $14.78 | -18.81% | 9 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $3 | $18.80 | -84.04% | 4 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $8 | $2.52 | +217.46% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $5 | $14.06 | -64.44% | 10 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $52 | $39.98 | +30.07% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $6.06 | +246.53% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $12 | $13.62 | -11.89% | 3 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $3.04 | -1.32% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $12 → $10 | $15.63 | -36.02% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $205.83 | +9.31% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $16.08 | +18.20% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $6.02 | +215.61% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.13 | +2,112.39% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $13.14 | +1,193.76% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $6.37 | +25.59% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $132.39 | +1.97% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $37.68 | +696.18% | 2 | Mar 30, 2020 |
Vera Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $95
Current: $46.51
Upside: +104.26%
Cytokinetics
Dec 19, 2025
Upgrades: Buy
Price Target: $55 → $95
Current: $62.58
Upside: +51.81%
PTC Therapeutics
Nov 5, 2025
Maintains: Sell
Price Target: $44 → $50
Current: $72.48
Upside: -31.02%
BridgeBio Pharma
Oct 31, 2025
Maintains: Buy
Price Target: $55 → $100
Current: $76.26
Upside: +31.13%
Kiniksa Pharmaceuticals International,
Oct 29, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $39.41
Upside: +39.56%
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $12.20
Upside: -50.82%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $64.25
Upside: +19.84%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $27.39
Upside: -26.98%
Exelixis
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $43.96
Upside: +6.92%
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $14.78
Upside: -18.81%
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $18.80
Upside: -84.04%
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $2.52
Upside: +217.46%
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $14.06
Upside: -64.44%
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $39.98
Upside: +30.07%
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $6.06
Upside: +246.53%
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $13.62
Upside: -11.89%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $3.04
Upside: -1.32%
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $15.63
Upside: -36.02%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $205.83
Upside: +9.31%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $16.08
Upside: +18.20%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $6.02
Upside: +215.61%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.13
Upside: +2,112.39%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $13.14
Upside: +1,193.76%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $6.37
Upside: +25.59%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $132.39
Upside: +1.97%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $37.68
Upside: +696.18%